Todays Report: The Selecta Biosciences Inc. (SELB) Rating Lowered to Hold at Zacks Investment Research

The Selecta Biosciences Inc. (SELB) Rating Lowered to Hold at Zacks Investment Research

Selecta Biosciences Inc. (NASDAQ:SELB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “

SELB has been the topic of several other research reports. Canaccord Genuity assumed coverage on Selecta Biosciences in a report on Monday, July 18th. They issued a “buy” rating and a $20.00 price objective on the stock. Needham & Company LLC assumed coverage on Selecta Biosciences in a report on Monday, July 18th. They issued a “buy” rating and a $28.00 price objective on the stock. Finally, Stifel Nicolaus assumed coverage on Selecta Biosciences in a report on Monday, July 18th. They issued a “buy” rating and a $23.00 price objective on the stock.

Selecta Biosciences (NASDAQ:SELB) opened at 16.21 on Wednesday. The stock has a 50 day moving average price of $13.97 and a 200 day moving average price of $13.35. Selecta Biosciences has a 52 week low of $10.26 and a 52 week high of $18.88.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Polaris Venture Management Co. V L.L.C. bought a new position in Selecta Biosciences during the second quarter valued at approximately $26,919,000. Monashee Investment Management LLC bought a new position in Selecta Biosciences during the second quarter valued at approximately $350,000. JPMorgan Chase & Co. bought a new position in Selecta Biosciences during the second quarter valued at approximately $4,215,000. Vanguard Group Inc. bought a new position in Selecta Biosciences during the second quarter valued at approximately $1,679,000. Finally, FMR LLC bought a new position in Selecta Biosciences during the second quarter valued at approximately $3,997,000. 41.02% of the stock is owned by hedge funds and other institutional investors.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.

Related posts

Leave a Comment